Sanjiban Pharma

Vaxirab N (Rabies Vaccine, Human IP) is used for active immunization to prevent rabies infection. It is a highly effective, inactivated vaccine used in two main scenarios: before potential exposure (pre-exposure prophylaxis) and after a suspected exposure (post-exposure prophylaxis). 

• Post-Exposure Prophylaxis (PEP): This is for individuals who have been potentially exposed to the rabies virus through animal bites, scratches, or contact with an infected animal's saliva on broken skin or mucous membranes. In this case, the vaccine is administered as part of an immediate treatment regimen that typically includes thorough wound cleansing and, for those not previously vaccinated, the administration of human rabies immunoglobulin (HRIG).
• Pre-Exposure Prophylaxis (PrEP): This is for individuals at a higher risk of coming into contact with the rabies virus as part of their work or travel. High-risk groups include:
  • Veterinarians, animal handlers, and zookeepers.
  • Personnel in rabies research laboratories.
  • Hunters, forest rangers, and abattoir workers in endemic areas.
  • Travelers to parts of the world where rabies is common and medical care might be limited. 

Additional Information:

• Delivery Time: Within City half an hour
• Packaging Details: box